Last reviewed · How we verify
Placebo of PR tablet
Placebo of PR tablet is a Small molecule drug developed by Reckitt Benckiser Healthcare (UK) Limited. It is currently in Phase 3 development.
A placebo tablet contains no active pharmaceutical ingredient and produces no direct pharmacological effect.
At a glance
| Generic name | Placebo of PR tablet |
|---|---|
| Sponsor | Reckitt Benckiser Healthcare (UK) Limited |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Placebos are inert formulations used as control comparators in clinical trials to distinguish the true pharmacological effects of an active drug from placebo response (psychological and contextual effects). In a Phase 3 trial, the placebo PR tablet serves as the comparator arm to evaluate the efficacy and safety of the active investigational drug.
Approved indications
Common side effects
Key clinical trials
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
- Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer (PHASE2)
- Teriflunomide vs. Placebo During Gluten Challenge in Celiac Disease (PHASE1, PHASE2)
- Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer (PHASE3)
- Folic Acid Supplement Versus Placebo for Treating Mucositis Adverse Events in Metastatic Renal Cell Carcinoma Patients Receiving Targeted Therapy (PHASE2)
- Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™ (PHASE3)
- Efficacy of 300 mg Ibuprofen Prolonged-Release Tablets for the Treatment of Pain After Surgical Removal of Impacted Third Molars (PHASE3)
- Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo of PR tablet CI brief — competitive landscape report
- Placebo of PR tablet updates RSS · CI watch RSS
- Reckitt Benckiser Healthcare (UK) Limited portfolio CI